Overall rank by patents
#47,979
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
Jumpcode holds 5 US patents across 3 technology areas, rank #47,979 of 50,000 tracked assignees.
Jumpcode Genomics, Inc. has been granted 5 US utility patents between 2020 and 2023, placing Jumpcode Genomics, Inc. at rank #47,979 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.2 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Jumpcode Genomics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Jumpcode sits between Jubilant Biosys Limited (5 patents, rank #47,975) and JVD, Inc. (5 patents, rank #47,983) - the closest US assignees by grant volume. The composite Innovation Score of 29.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Jumpcode Genomics, Inc.'s 12.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Jumpcode Genomics, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
JUBILANT BIOSYS LIMITED
5 patents
JUGGERNAUT TACTICAL, INC.
5 patents
JUICE TECHNOLOGY AG
5 patents
JULIUS SAMANN LTD.
5 patents
JUROP S.P.A.
5 patents
JUSTEQ, LLC
5 patents
JUVALIPS, LLC
5 patents
JVD, INC.
5 patents
JUMPCODE GENOMICS, INC.
5 patents
What this shows Jumpcode holds 5 patents at rank #47,979, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #47,979 in granted patent volume.
Other assignees with the most granted patents in Jumpcode's primary technology class.
Jumpcode's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 69% higher than 31% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 20.0% |
| 2021 | 1 | 20.0% |
| 2022 | 1 | 20.0% |
| 2023 | 2 | 40.0% |
Top 3 of 3 technology areas
Overall rank by patents
#47,979
Across all tracked assignees
29.6 out of 100
How to use this portfolio
Jumpcode's 5 grants land it in the top 69% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.